Abstract:e16119 Background: The therapeutic strategy for recurrent hepatocellular carcinoma (HCC) after hepatectomy is limited. There is a significantly unmet clinical need for effective treatment options for these patients. This study aimed to assess the clinical efficacy and safety of regorafenib alone or combined with a PD-1 inhibitor as a second or further-line treatment for patients with recurrent HCC after hepatectomy. Methods: Patients receiving regorafenib alone or combined with a PD-1 inhibitor in Peking University People’s Hospital from January 2019 to November 2022 were entered prospectively into a clinical database. Data were retrospectively analyzed. The major inclusion criteria were: histologically confirmed diagnosis of HCC; disease recurrence after radical hepatectomy; with tumor that cannot be re-resected; ECOG performance status score (PS) ≤2. Regorafenib was administered at the daily dose of 80-120 mg for more than 4 weeks. Progression-free survival (PFS) was the primary endpoint. The second outcomes included PFS, objective response rate (ORR), disease control rate (DCR), and the incidence of drug-related adverse events (AEs). CTCAE v5.0 was used for evaluation of AEs. Results: Twenty-two patients were enrolled with a median age of 59. The hepatic function of all patients was mildly impaired (Child-Pugh A). Among all patients, 36.35% of cases were enrolled in Barcelona Clinic Liver Clinic (BCLC) A and the remainder were in BCLC B. Eight cases (36.36%) received regorafenib in combination with PD-1 inhibitor therapy and 14 cases received regorafenib treatment alone. Among all patients, 86.36% of the cases were treated with regorafenib as second-line therapy. Five patients (22.73%) had extrahepatic metastasis. The median PFS and overall survival (OS) were 11.66 (±10.20) months and 16.92 (±10.21) months, respectively. The 3-month PFS rate was 100%. The 6-month and 12-month PFS rates were 75% (95%CI: 58.49%-96.70%) and 53.33% (95%CI: 34.88%-81.50%), respectively. The results showed a significant difference in median PFS between patients receiving regorafenib as second-line therapy and third-line therapy [12.30 months (95%CI: 4.25-20.36) vs 4.30 months (95%CI: 3.50-5.10); P<0.001]. In addition, there is a significant difference in median PFS between patients with extrahepatic metastasis and those without extrahepatic metastasis [5.20 months (95%CI: 3.48-6.92) vs 18.20 months (95%CI: 5.09-31.31; P=0.003)]. The ORR and DCR were 18.18% and 81.82%. The most frequent AEs were hand-foot syndrome (40.91%), pain (18.18%), diarrhea (13.64%), and hypertension (13.64%). Most AEs were grade 1 or 2, with only 1 case having grade 3 AE. Conclusions: Regorafenib alone or combined with a PD-1 inhibitor showed significant clinical efficacy in controlling the disease progression of recurrent HCC.

Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.

Efficacy and Safety of PD‐1 Inhibitor Combined with Antiangiogenic Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study

Clinical efficacy and safety of regorafenib for patients with recurrent hepatocellular carcinoma after hepatectomy: A real-world study in China.

Study on Efficacy and Safety of Transcatheter Arterial Chemoembolization (TACE) Combined with Regorafenib and PD-1 Antibody Versus Continued TACE Combined with Regorafenib in Patients with Hepatocellular Carcinoma after Failed Second-Line Treatment with Regorafenib.

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

Analysis of clinical efficacy and long-term prognosis of patients with hepatocellular carcinoma treated with PD-L1 inhibitor targeting

Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study

Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

A retrospective study on the efficacy and safety of regorafenib alone or in combination in advanced hepatocellular carcinoma.

A Real-World Study of TACE Combined with Regorafenib As a Second-Line Treatment for Advanced Hepatocellular Carcinoma

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study

Regorafenib plus programmed death‐1 inhibitors vs. regorafenib monotherapy in second‐line treatment for advanced hepatocellular carcinoma: A systematic review and meta‐analysis

Study on Safety and Efficacy of Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First-Line Targeted Therapy.

Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma